Enzon Pharmaceuticals
{{Short description|American pharmaceutical company}}
{{multiple issues|
{{notability|corp|date=March 2014}}
{{third-party|date=December 2013}}
}}
{{Infobox company
| name = Enzon Pharmaceuticals, Inc.
| logo =
| type = Public
| traded_as = {{ubl|{{OTCQX|ENZN}}|{{NASDAQ was|ENZN}}}}
| location = Piscataway, New Jersey
| industry = Biotechnology
| foundation = {{start date and age|1981}}{{cite web|url=https://finance.yahoo.com/q?s=ENZN |title=Business Summary |accessdate=Dec 22, 2013}}
| products = Drugs
| location_city = Piscataway, New Jersey
| location_country = United States
| revenue = $ 34.49M (Dec31, 2013){{cite web |url= https://finance.yahoo.com/q/ks?s=ENZN+Key+Statistics |title= Company Key Statistics}}
| key_people = George W. Hebard III, M.B.A. (CEO, Interim Principal Executive Officer, Interim Chief Operating Officer)
Richard L. Feinstein CPA
({{small| Principal Financial Officer, Principal Accounting Officer}}) (Dec 31, 2012)){{cite web |url= https://www.google.com/finance/?cid=197696 |title= Company Officers and directors}}
| homepage = {{URL|http://enzon.com/}}
}}
Enzon Pharmaceuticals, Inc. is a pharmaceutical company.{{cite web|url=http://enzon.com/ |title=History|accessdate=Dec 20, 2013}} Its headquarters is in Piscataway, New Jersey.{{cite web|url=https://finance.yahoo.com/q?s=ENZN | title=profile| accessdate=Dec 23, 2013}} The company is a publicly traded company on NASDAQ under the symbol "ENZN". It's also doing marketing works in Asia areas such as China. In 2012, the company orally presented in Nanjing, China about the symposium of its drug delivery systems, which help improve therapeutic molecules' pharmaceutical properties.{{cite news|url=https://www.reuters.com/article/2012/11/08/idUS146220+08-Nov-2012+MW20121108 |archive-url=https://web.archive.org/web/20131227044722/http://www.reuters.com/article/2012/11/08/idUS146220+08-Nov-2012+MW20121108 |url-status=dead |archive-date=27 December 2013 | title=Enzon Announces Two Oral Presentations| accessdate=Dec 26, 2013 | work=Reuters| date=8 November 2012}}
History
Enzon Pharmaceuticals, Inc started its earliest business in 1981. Now, the focus of the company is mainly on development and production of drugs for cancer patients.{{cite web|url=http://enzon.com |title=History|accessdate=Dec 20, 2013}} It is also actively researching on improving the chemical attachment of PEG to help provide antibodies in molecules.{{cite news|url=https://www.reuters.com/article/2012/11/08/idUS146220+08-Nov-2012+MW20121108 |archive-url=https://web.archive.org/web/20131227044722/http://www.reuters.com/article/2012/11/08/idUS146220+08-Nov-2012+MW20121108 |url-status=dead |archive-date=27 December 2013 | title=Enzon Announces Two Oral Presentations| accessdate=Dec 26, 2013 | work=Reuters| date=8 November 2012}}
In 2010, Enzon Pharmaceuticals, Inc.sold its specialty pharmaceutical business to the sigma-tau Group (sigma-tau).{{cite web |url=http://www.thefreelibrary.com/Enzon+Completes+Sale+of+Specialty+Pharmaceutical+Business.-a0217804746|title=Enzon Completes Sale of Specialty Pharmaceutical Business}}{{cite web | url = https://finance.yahoo.com/q/pr?s=ENZN+Profile |title= Company Business Summary}}
Production
The products of Enzon Pharmaceuticals, Inc include four principal compounds of different clinical development, as well as several novel mRNA antagonists in preclinical research.{{cite web|url=http://investor.enzon.com/ |title=Investors|accessdate=Dec 25, 2013}}
Research & Development
In July 2012, Enzon Pharmaceuticals presented the result from pre-clinical studies about human interferon-beta-1b (IFN-β-1b) and an anti-TNF-α antibody fragment (Fab) through releasable PEGylation at the 39th Annual Meeting & Exposition of the Controlled Release Society.{{cite web|url=http://investor.enzon.com/releasedetail.cfm?ReleaseID=692106|title=Enzon Presents Pre-Clinical Data on Controlled Release of PEGylated Interferon-Beta-1b and PEGylated anti-TNF-a Antibody Fragment at the Controlled Release Society Annual Meeting}}
In June 2012, Enzon Pharmaceuticals presented the Phase I study of PEG-SN38 in children with recurrent or refractory neuroblastoma and other solid tumors at the 2012 Advances in Neuroblastoma Research Conference.{{cite web|url=https://www.drugs.com/clinical_trials/enzon-announces-data-phase-study-peg-sn38-pediatric-neuroblastoma-other-solid-tumors-presented-2012-13912.html|title=Enzon Announces Data From Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference}} In the same month, the company presented the Phase II study in which PEG-SN38 demonstrated notable activity in patients with previously treated metastatic breast at the American Society of Clinical Oncology Meeting.{{cite web|url=https://www.drugs.com/clinical_trials/enzon-presents-final-analysis-phase-ii-peg-sn38-ezn-2208-study-patients-metastatic-breast-cancer-13752.html|title=Enzon Presents Final Analysis of Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer at 2012 ASCO Meeting}}
In May 2012, Enzon Pharmaceuticals reached a strategic partnership using Enzon's PEGylation linker technology and PEG-SN38 (EZN-2208) in China.{{cite web|url=http://files.shareholder.com/downloads/ENZON/0x0x566806/f0141f4a-218f-424b-bce9-ac51854b6e4f/ENZN_News_2012_5_7_General.pdf|title=Enzon and Hisun Announce Strategic Alliance for Enzon's Customized PEGylation Linker Technology and Licensing Agreement for PEG-SN38 in China}}
Corporate affairs
= Stocks =
The ticker symbol for Enzon Pharmaceuticals, Inc is "ENZN", which was traded on NASDAQ.{{cite web|url=https://finance.yahoo.com/q?s=ENZN |title=Business Summary|accessdate=Dec 22, 2013}}
=Scandals=
The company has recently launched a nationwide recall of OMONTYS injection because of reports on serious hypersensitivity reactions, including possible life-threatening anaphylaxis.{{cite web|url=http://apps.shareholder.com/sec/viewerContent.aspx?companyid=ENZON&docid=1901126 |title=SECURITIES AND EXCHANGE COMMISSION|accessdate=Dec 25, 2013}}
References
{{Reflist}}
External links
- [http://enzon.com Official Website]
{{Authority control}}
Category:Companies formerly listed on the Nasdaq
Category:Companies traded over-the-counter in the United States